Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review.
PD-L1
PSCC
Penile squamous cell carcinoma
biomarker
immunotherapy
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
09
2019
accepted:
19
03
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
6
5
2020
Statut:
epublish
Résumé
Penile squamous cell carcinoma (PSCC) bears poor prognosis due to its rarity and limited treatment options, especially after failure of standard treatments. Effective therapeutic options were desperately needed. We report a recurrent metastatic PSCC patient with positive programmed death ligand 1 (PD-L1) expression (≥10%) and tumor mutation burden (TMB) of 8.87 (Muts/Mb) who obtained significant response to immunotherapy, with progression-free survival (PFS) exceeding 10 months. This is the first case presenting remarkable response to immunotherapy in a Chinese PSCC patient. The remarkable response might be associated with PD-L1 expression, indicating that PD-L1 expression could be a promising biomarker for immunotherapy in PSCC. TMB ranking may also contribute to patient selection. However, large clinical trials are needed to validate these notions.
Sections du résumé
BACKGROUND
BACKGROUND
Penile squamous cell carcinoma (PSCC) bears poor prognosis due to its rarity and limited treatment options, especially after failure of standard treatments. Effective therapeutic options were desperately needed.
CASE PRESENTATION
METHODS
We report a recurrent metastatic PSCC patient with positive programmed death ligand 1 (PD-L1) expression (≥10%) and tumor mutation burden (TMB) of 8.87 (Muts/Mb) who obtained significant response to immunotherapy, with progression-free survival (PFS) exceeding 10 months.
CONCLUSION
CONCLUSIONS
This is the first case presenting remarkable response to immunotherapy in a Chinese PSCC patient. The remarkable response might be associated with PD-L1 expression, indicating that PD-L1 expression could be a promising biomarker for immunotherapy in PSCC. TMB ranking may also contribute to patient selection. However, large clinical trials are needed to validate these notions.
Identifiants
pubmed: 32368090
doi: 10.2147/OTT.S231258
pii: 231258
pmc: PMC7183339
doi:
Types de publication
Case Reports
Langues
eng
Pagination
3319-3324Informations de copyright
© 2020 Su et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests in this work.
Références
J Urol. 2017 Mar;197(3 Pt 1):690-697
pubmed: 27697578
Front Immunol. 2018 Jun 11;9:1253
pubmed: 29942303
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Dtsch Arztebl Int. 2018 Sep 28;115(39):646-652
pubmed: 30375327
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
J Cancer. 2018 Jun 6;9(13):2302-2307
pubmed: 30026825
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Case Rep Oncol Med. 2019 Mar 25;2019:8349793
pubmed: 31019822
Eur Urol Focus. 2019 Sep;5(5):718-721
pubmed: 30862420
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
World J Urol. 2020 Mar;38(3):725-732
pubmed: 31297629
Cancer Lett. 2018 Feb 1;414:166-173
pubmed: 29155348
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Oncoimmunology. 2016 Dec 22;6(2):e1269047
pubmed: 28344882
Ann Oncol. 2016 Sep;27(9):1706-12
pubmed: 27217541
Urology. 2015 May;85(5):1104-1110
pubmed: 25819619
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851